Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We with Cardiac Cell-Based Therapy?

Circulation Research

Volumn 117, Issue 3, 2015, Pages 229-233

  Sanina, Cristina ^a   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

cell and tissue based therapy; chronic heart failure; clinical trial; heart disease; mesenchymal stem cells

Indexed keywords

BIOLOGICAL THERAPY; CELL THERAPY; HEART DISEASE; HUMAN; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TREATMENT FAILURE; ADVERSE EFFECTS; ALLOGRAFT; ANIMAL; AUTOTRANSPLANTATION; BIOASSAY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; HEART FAILURE; MULTICENTER STUDY (TOPIC); MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PILOT STUDY; PROCEDURES; REGENERATIVE MEDICINE; TREATMENT OUTCOME; TRENDS;

ALLOGRAFTS; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ENDPOINT DETERMINATION; HEART FAILURE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PILOT PROJECTS; REGENERATIVE MEDICINE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84937554663     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.306306     Document Type: Review

References (23)

1. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res. 2015;116:1413-1430. doi: 10.1161/CIRCRESAHA.116.303614.
2. Nowbar AN, Mielewczik M, Karavassilis M, Dehbi HM, Shun-Shin MJ, Jones S, Howard JP, Cole GD, Francis DP; DAMASCENE writing group. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ. 2014;348:g2688.
3. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9:11-15. doi: 10.1016/j.stem.2011.06.008.
4. Hare JM, Sanina C. Bone marrow mononuclear cell therapy and granulocyte colony-stimulating factor for acute myocardial infarction: Is it time to reconsider? J Am Coll Cardiol. 2015;65:2383-2387. doi: 10.1016/j. jacc.2015.03.571.
5. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109:923-940. doi: 10.1161/CIRCRESAHA.111.243147.
6. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, Morales AR, Da Silva J, Sussman MA, Heldman AW, Hare JM. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation. 2013;127:213-223. doi: 10.1161/CIRCULATIONAHA.112.131110.
7. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-2286. doi: 10.1016/j.jacc.2009.06.055.
8. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40-51. doi: 10.1038/nbt.2786.
9. Butler D. Translational research: crossing the valley of death. Nature. 2008;453:840-842. doi: 10.1038/453840a.
10. A tale of two drugs. Nat Rev Drug Discov. 2006;5:803. http://www.nature.com/nrd/journal/v5/n10/full/nrd2167.html.
11. McCall FC, Telukuntla KS, Karantalis V, Suncion VY, Heldman AW, Mushtaq M, Williams AR, Hare JM. Myocardial infarction and intramyocardial injection models in swine. Nat Protoc. 2012;7:1479-1496. doi: 10.1038/nprot.2012.075.
12. Huang CC, Tsai HW, Lee WY, Lin WW, Chen DY, Hung YW, Chen JW, Hwang SM, Chang Y, Sung HW. A translational approach in using cell sheet fragments of autologous bone marrow-derived mesenchymal stem cells for cellular cardiomyoplasty in a porcine model. Biomaterials. 2013;34:4582-4591. doi: 10.1016/j.biomaterials.2013.03.003.
13. Ledford H. Translational research: 4 ways to fix the clinical trial. Nature. 2011;477:526-528. doi: 10.1038/477526a.
14. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13:419-431. doi: 10.1038/nrd4309.
15. Odom DT, Dowell RD, Jacobsen ES, Gordon W, Danford TW, MacIsaac KD, Rolfe PA, Conboy CM, Gifford DK, Fraenkel E. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat Genet. 2007;39:730-732. doi: 10.1038/ng2047.
16. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369-2379. doi: 10.1001/jama.2012.25321.
17. Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311:62-73. doi: 10.1001/jama.2013.282909.
18. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379:895-904. doi: 10.1016/S0140-6736(12)60195-0.
19. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61:2329-2338. doi: 10.1016/j. jacc.2013.02.071.
20. Chugh AR, Beache GM, Loughran JH, Mewton N, Elmore JB, Kajstura J, Pappas P, Tatooles A, Stoddard MF, Lima JA, Slaughter MS, Anversa P, Bolli R. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012;126:S54-S64. doi: 10.1161/CIRCULATIONAHA.112.092627.
21. Lee JW, Lee SH, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Kwon W, Hong IS, Lee K, Kwan J, Park KS, Choi D, Jang YS, Hong MK. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean Med Sci. 2014;29:23-31. doi: 10.3346/jkms.2014.29.1.23.
22. Naftali-Shani N, Itzhaki-Alfia A, Landa-Rouben N, et al. The origin of human mesenchymal stromal cells dictates their reparative properties. J Am Heart Assoc. 2013;2:e000253. doi: 10.1161/JAHA.113.000253.
23. Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang P, Traverse JH, Krum H, Skerrett D, Zheng Y, Willerson JT, Itescu S, Henry TD. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or non-ischemic heart failure [published online before print July 6, 2015]. Circ Res. doi: 10.1161/CIRCRESAHA.115.306332.